Skip to main content
Top

Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist

Abstract

Functioning gonadotroph pituitary neuroendocrine tumors (Gn-PitNETs) cause ovarian hyperstimulation. We report Gn-PitNETs, including a distant metastasis case responsive to a dopamine agonist (DA), cabergoline. A 10-year-old girl presented with ovarian enlargement and elevated FSH levels (33.7 mIU/mL). A pituitary tumor was resected and confirmed as a Gn-PitNET. Radiotherapy for residual tumor improved ovarian enlargement. At age 20, ovarian enlargement recurred and cabergoline relieved symptoms and decreased FSH levels. At age 35, ovarian enlargement recurred after discontinuing cabergoline but improved with its reinstatement. Liver biopsy confirmed metastatic Gn-PitNET and DRD2 positivity. A 26-year-old woman presented with ovarian enlargement and elevated FSH levels (31.6 mIU/mL). A pituitary tumor was resected and confirmed as a Gn-PitNET with negative DRD2. FSH levels normalized, and ovarian size improved. A 48-year-old man presented with bitemporal hemianopia. FSH levels were elevated (251.4 mIU/mL) without testicular enlargement. The pituitary tumor was resected, improving hemianopia and normalizing FSH levels. Histopathology confirmed a Gn-PitNET with strong FSH staining and DRD2 positivity. In a rare case of metastatic Gn-PitNET, cabergoline was associated with tumor stability and hormone control. Further studies may clarify whether DRD2 expression can help predict DA responsiveness in refractory tumors.
(200/200 words)
Title
Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist
Authors
Ken Uekawa
Naoki Shinojima
Takahiro Yamamoto
Shigeo Anai
Kozo Tashima
Motoyuki Igata
Takeshi Matsumura
Rumi Sasaki
Takashi Ohba
Hironori Tashiro
Kazuhito Tanaka
Kentaro Tanaka
Hiroyo Mabe
Shigetoshi Yano
Toshinori Hirai
Yoshiki Mikami
Akitake Mukasa
Publication date
16-11-2025
Publisher
Springer Nature Singapore
Published in
Brain Tumor Pathology
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-025-00521-3
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Learn more
Image Credits
Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME